: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces First Quarter 2016 Financial Results Utica, New York

CONMED Corporation Announces

First Quarter 2016 Financial Results

Utica, New York, April 27, 2016

--- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the first quarter ended March 31, 2016.

First Quarter 2016 Highlights

"We accomplished several important

milestones in the quarter, and we are pleased with our sales growth in General Surgery. Further, the contribution from the AirSeal

System was in line with our expectations," commented Curt R. Hartman, CONMED's President and Chief Executive Officer.

"Despite a slow start to the year for capital sales in the international markets, we saw growth in all three of our main

product categories domestically, with U.S. Orthopedics posting its third consecutive quarter of positive growth. We remain confident

in our financial outlook for the year as investments in our strategic initiatives and in product development translate into further

operating improvements."

For the quarter ended March 31,

2016, domestic sales, which represented 53.0% of total revenue, increased 10.4% as a result of growth across all three of the Company's

product categories, led by General Surgery. The SurgiQuest acquisition contributed to 19.4% year-over-year growth in the U.S. General

Surgery business. International sales, which represented 47.0% of total revenue, declined 6.4% compared to the first quarter of

2015 on a reported basis. Foreign currency exchange rates, including the effects of the FX hedging program, had a negative impact

of $5.7 million on first quarter sales. In constant currency, international sales decreased 0.3% versus the prior-year period.

For the quarter ended March 31,

2016, reported net loss totaled $2.3 million, compared to reported net earnings of $6.3 million a year ago. Reported diluted net

loss per share was $0.08 in the quarter, compared to reported diluted net earnings per share of $0.23 in the prior-year period.

Reported net loss for 2016 includes business acquisition, restructuring, and debt refinancing costs, and reported net earnings

for 2015 include restructuring costs. The effect of each of these items on reported net earnings/loss and reported diluted net

earnings/loss per share appears in the reconciliation of GAAP to non-GAAP measures below.

As previously announced, beginning

in 2016, the Company is excluding after-tax costs of special items including acquisitions, restructuring, and debt refinancing,

as well as amortization of intangible assets, net of tax, from its adjusted diluted net earnings per share. Excluding the impact

of these items, adjusted net earnings(2) of $11.6 million decreased 15.3% year over year and adjusted diluted net earnings

per share (1) of $0.42 decreased 14.3% year over year. The decline in adjusted net earnings was largely attributable

to the impact of unfavorable foreign exchange rates, partially offset by a lower tax rate and improved gross margin during the

The Company is revising its 2016

guidance for reported sales and adjusted diluted net earnings per share higher due to the updated foreign exchange impact anticipated

for the year. The Company now forecasts reported 2016 sales in the range of $768 to $778 million, compared to the previous range

of $760 to $770 million. This revenue forecast includes constant currency organic sales growth of 1% to 3%, sales related to the

SurgiQuest acquisition of $55 to $60 million, and an updated negative impact of foreign exchange of $13 to $15 million (based on

foreign currency exchange rates as of April 22, 2016).

Based on its revised 2016 reported

sales estimate range of $768 to $778 million, the Company now forecasts 2016 adjusted diluted net earnings per share in the range

of $1.95 to $2.05, compared to the previous range of $1.85 to $1.95, which reflects the favorable movement in foreign exchange

rates. The adjusted diluted net earnings per share estimates for 2016 exclude the cost of special items including acquisition costs,

restructuring costs, and debt refinancing, which are estimated in the range of $18 to $20 million, net of tax, and amortization

of intangible assets, which are now estimated in the range of $12 to $14 million, net of tax, compared to the previous range of

$14 to $16 million, net of tax, based on the close of the SurgiQuest transaction.

Supplemental Financial Disclosures

(1) A reconciliation

of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure appears below.

(2) A reconciliation

of reported net earnings to adjusted net earnings, a non-GAAP financial measure appears below.

In conjunction with this earnings

press release, CONMED has prepared supplemental financial disclosures which are available on the home page of the "Investors

- Financial Reports" section of the Company's web site at www.conmed.com.

The Company's management will

host a conference call today at 4:30 p.m. ET to discuss its first quarter 2016 results.

To participate in the conference

call, dial 877-573-5235 (domestic) or 503-406-4448 (international) and enter the passcode 83879064.

This conference call will also

be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast

replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will

also be available from 7:30 p.m. ET on Wednesday, April 27, 2016 until 11:59 p.m. ET on Wednesday, May 4, 2016. To hear this recording,

dial 855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 83879064.

About CONMED Corporation

CONMED is a medical technology

company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used

by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

The Company distributes its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 17

countries and international sales constitute approximately 50% of the Company's total sales. Headquartered in Utica, New

York, the Company employs approximately 3,400 people. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and today's

conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties,

which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements

herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause

actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks

factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Any and all forward-looking

statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to

the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have

a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in

the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation

of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting

of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain

non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding

specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted effective income tax rate; adjusted

net earnings and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful

information to assist investors and shareholders in understanding our financial results and assessing our prospects for future

performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are

important indicators of our operations because they exclude items that may not be indicative of, or are unrelated to, our core

operating results and provide a baseline for analyzing trends in the Company's underlying businesses. Further, the presentation

of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's cash flow. Management

uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection

with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

To measure percentage sales growth

in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability

and trend of sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that

affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not

be indicative of our past and future performance and are therefore excluded to allow investors to better understand underlying

Because non-GAAP financial measures